FRAMINGHAM, MA, July 6, 2006-GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present on Wednesday, July 12, 2006 at 9:28 a.m. Eastern Time during the C.E. Unterberg, Towbin Emerging Growth Conference. The conference is being held at the Mandarin Oriental Hotel, New York, New York from July 11-12, 2006.
The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation.
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC's ATrynŽ, a recombinant form of human antithrombin, has received a positive opinion for market authorization in Europe to treat hereditary deficient patients in surgical situations and is in a pivotal Phase III study for the United States. In addition to the ATrynŽ program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. GTC also enters into partnering arrangements, or external programs, in which its technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of GTC's external programs that is a transgenically produced product is in clinical trials. Additional information is available on the GTC web site, http://www.gtc-bio.com.
CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.
Francesca DeVellis (investors)
(617) 577-8110
Copyright 2006 GTC Biotherapeutics, All Rights Reserved